Liposomal Formulations

AERx Inhalation Technology Platform

Intellectual Property


Liposomal Formulations for Inhalation

• “Nanopackaging” of drugs
• Sustained release within lung
• Ideal for AERx platform
• Applicable to multiple products

Aradigm’s liposome formulations are nano-size liquid vesicles made out of lipids that encapsulate drugs. When the drug in these vesicles is deposited in the respiratory tract, it is slowly released, with the view to provide sustained delivery of the drug at the site of action and only minimum concentration of the drug in the rest of the body. Purposeful formulations of liposomes can also achieve preferential targeting of drugs to certain cell types, maximizing the efficacy of and minimizing the toxicity of the drug.

Scientific Publications
Cipolla D. et al. Development of Liposomal Ciprofloxacin to Treat Lung Infections. Pharmaceutics. 2016. 8(1): 6. | Supplementary Material

Cipolla D. et al. Formation of Drug Nanocrystals under Nanoconfinement Afforded by Liposomes. RSC Advances. 2016. 6: 6223-6233.

Cipolla D. et al. Emerging Opportunities for Inhaled Antimicrobial Therapy. J Antimicro. 2015. 1(1): 104.

Cipolla D. et al. Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals. J Aer Med Pulm Drug Del. 2015. 28(6): 411-422.

Cipolla D. et al. Comment on: Inhaled antimicrobial therapy-Barriers to effective treatment. Adv. Drug Deliv. Rev. 2015. 85: e6-e7.

Norville IH. et al. Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever. Antimicrob Agents Chemother. 2014. 58: 5510-5518.

Cipolla D. et al. Aerosol Performance and Long Term Stability of Surfactant-Associated Liposomal Ciprofloxacin Formulations with Modified Encapsulation and Release Properties. AAPS PharmSciTech. 2014. 15(5): 1218-1227.

Hamblin KA. et al. The Potential of Liposome-Encapsulated Ciprofloxacin as a Tularemia Therapy. Front Cell Infect Microbiol. 2014. 4: 79

Cipolla D et al. Modifying the Release Properties of Liposomes toward Personalized Medicine. J. Pharm Sci. 2014. 103(6): 1851-1862.

Darweesh RS. And Sakagami M. In Vitro Inhibitory Activities of Liposomal Ciprofloxacin Against Lipopolysaccharide (LPS)-Induced IL-8 Release from the Calu-3 Cells. RDD 2014. Dalby R.N. et al. (eds). 2014. 747-750.

Cipolla D. et al. Development and Characterization of an In Vitro Release Assay for Liposomal Ciprofloxacin for Inhalation. J. Pharm. Sci. 2014. 103(1): 314-327.

Hamblin KA. Et al. Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4. Antimicrob Agents Chemother. 2014. 58: 3053-3059.

Cipolla D et al. Liposomal Formulations for Inhalation. Ther Delivery. 2013. 4(8): 1047-1072.

Ong HX. et al. In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. Eur J Pharm Biopharm. 2013. 86(1): 83-89.

Cipolla D. et al. Liposomal Ciprofloxacin for Inhalation Retains Integrity Following Nebulization. RDD Europe 2013. Dalby R.N. et al. (eds). 2013. 237-242.

Serisier DJ. Et al. Inhaled, Dual-Release Liposomal Ciprofloxacin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-2) – a Randomised, Double-Blind, Placebo-Controlled Trial. Thorax. 2013. 68(9): 812-817.

Ong HX. etal. Liposomal Nanoparticles Control the Uptake of Ciprofloxacin Across Respiratory Epithelia. Pharm Res. 2012. 29(12): 3335-3346.

Ong HX. et al. Inhaled Liposomal Ciprofloxacin Nanoparticles Control the Release of Antibiotic at the Bronchial Epithelia. RDD 2012. Dalby R.N. et al. (eds). 2012. 851-854.

Cipolla D et al. Liposomes, niosomes and proniosomes - a critical update of their (commercial) development as inhaled products. RDD Europe 2011. Dalby R.N. et al. (eds). 2011. 41-54.

Cipolla D. Et al. Inhaled Liposomal Ciprofloxacin: In Vitro Properties and Aerosol Performance. RDD 2010. Dalby R.N. et al. (eds). 2010. 409-414.

Bruinenberg P. et al. Inhaled liposomal ciprofloxacin: Once a day management of respiratory infections. RDD 2010. Dalby R.N. et al. (eds). 2010. 73-82.

Blanchard, J. Pulmonary Drug Delivery as a First Response to Bioterrorism. RDD X. Dalby R.N. et al. (eds). 2006. 73-82.

Yim D. et al. The development of inhaled liposome-encapsulated ciprofloxacin to treat cystic fibrosis. RDD X. Dalby R.N. et al. (eds). 2006. 425-428.

Educational Links
For more information on inhalation therapy and aerosol delivery, refer to the following resources:

Aerosol Society










2019 Aradigm Corporation. All Rights Reserved.